We are live on
!
Find out more
AC
Armistice Capital Portfolio holdings
AUM
$5.62B
1-Year Est. Return
36.06%
This Fund
S&P 500
This Quarter
Est. Return
+13.99%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$7.33B
AUM Growth
+$796M
(+12%)
Cap. Flow
-$12M
Cap. Flow
% of AUM
-0.16%
Top 10 Holdings %
Top 10 Hldgs %
60.07%
Holding
377
New
123
Increased
61
Reduced
77
Closed
82
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$68.6M |
| 2 |
argenx
ARGX
|
+$55M |
| 3 |
Sanofi
SNY
|
+$50.7M |
| 4 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
+$50.5M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$48.6M |
| 2 |
Keurig Dr Pepper
KDP
|
+$45.5M |
| 3 |
Incyte
INCY
|
+$45.2M |
| 4 |
UnitedHealth
UNH
|
+$37.3M |
| 5 |
Campbell Soup
CPB
|
+$32M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.97% |
| 2 | Consumer Staples | 5.35% |
| 3 | Consumer Discretionary | 4.92% |
| 4 | Technology | 3.86% |
| 5 | Communication Services | 1.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Sol-Gel Technologies
SLGL
$288M
| $2.36M | 0.03% |
213,500
| – | – |
|
|
PTN
152
Palatin Technologies
PTN
$14.1M
| $2.35M | 0.03% |
+11,800
| New | +$1.3M |
|
|
NVNO
153
enVVeno Medical
NVNO
$7.39M
| $2.24M | 0.03% |
+12,457
| New | +$1.98M |
|
154
Restaurant Brands International
QSR
$25.8B
| $2.22M | 0.03% |
28,353
-42,014
| -60% | -$2.92M |
|
155
Signet Jewelers
SIG
$3.75B
| $2.15M | 0.03% |
20,000
+4,122
| +26% | +$338K |
|
|
DPRO
156
Draganfly
DPRO
$161M
| $1.99M | 0.03% |
+166,000
| New | +$2.48M |
|
157
Cosmos Holdings
COSM
$13.3M
| $1.88M | 0.03% |
+1,334,937
| New | +$1.53M |
|
158
Fortress Biotech
FBIO
$92.7M
| $1.79M | 0.02% |
+596,000
| New | +$1.58M |
|
159
Zevra Therapeutics
ZVRA
$622M
| $1.76M | 0.02% |
+268,000
| New | +$1.25M |
|
|
BLTE
160
Belite Bio
BLTE
$6.35B
| $1.65M | 0.02% |
+36,000
| New | +$1.38M |
|
161
X4 Pharmaceuticals
XFOR
$391M
| $1.62M | 0.02% |
64,533
-14,000
| -18% | -$340K |
|
|
QTEX
162
QTREX Quantum
QTEX
$60.2M
| $1.62M | 0.02% |
+1,528,000
| New | +$1.82M |
|
163
Tonix Pharmaceuticals
TNXP
$179M
| $1.52M | 0.02% |
1,178
+725
| +160% | +$1.17M |
|
164
Portillo's
PTLO
$338M
| $1.48M | 0.02% |
+93,000
| New | +$1.44M |
|
|
PPBT
165
Purple Biotech
PPBT
$1.4M
| $1.47M | 0.02% |
+9,411
| New | +$2.08M |
|
166
Electronic Arts
EA
$52.9B
| $1.45M | 0.02% |
+10,570
| New | +$1.4M |
|
167
Sweetgreen
SG
$725M
| $1.41M | 0.02% |
+125,000
| New | +$1.32M |
|
168
GE Aerospace
GE
$396B
| $1.4M | 0.02% |
+13,725
| New | +$1.27M |
|
|
HEPA
169
DELISTED
Hepion Pharmaceuticals
HEPA
| $1.35M | 0.02% |
8,360
+408
| +5% | +$77.2K |
|
|
UBX
170
DELISTED
Unity Biotechnology
UBX
| $1.33M | 0.02% |
+688,000
| New | +$1.28M |
|
171
Sprouts Farmers Market
SFM
$7.94B
| $1.22M | 0.02% |
+25,298
| New | +$1.11M |
|
172
Williams-Sonoma
WSM
$29.2B
| $1.17M | 0.02% |
+11,630
| New | +$1.01M |
|
|
OTRK
173
DELISTED
Ontrak
OTRK
| $1.16M | 0.02% |
+192,400
| New | +$1.97M |
|
|
KZIA
174
Kazia Therapeutics
KZIA
$137M
| $1.09M | 0.01% |
+49,511
| New | +$1.45M |
|
175
Hilton Grand Vacations
HGV
$3.66B
| $1.05M | 0.01% |
+26,165
| New | +$982K |
|
Similar funds
CRC
RMDI
F
EW
O
DSC
ACM
PI
Armistice Capital's Q4 2023 Portfolio in Review
As of Q4 2023, Armistice Capital held 377 positions worth $7.33B, up 12% from $6.53B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Armistice Capital's Q4 2023 filing shows 123 new, 61 increased, 77 reduced and 82 closed positions. Its largest new stake was Sanofi: 1,036,000 shares worth $51.5M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $48.6M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 34% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.
- Armistice Capital's largest Q4 2023 buy was Sanofi: 1,036,000 shares worth $51.5M.
- Armistice Capital added most to GSK in Q4 2023, an estimated $68.6M increase.
- Armistice Capital's biggest Q4 2023 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $48.6M.
- Armistice Capital fully exited Keurig Dr Pepper in Q4 2023, selling an estimated $45.5M.
- Armistice Capital's ten largest holdings make up 60% of its $7.33B portfolio in Q4 2023.
- Armistice Capital opened 123 new positions and closed 82 in Q4 2023.
- Armistice Capital's portfolio value rose 12% quarter-over-quarter to $7.33B.
Based on Armistice Capital's 13F filing for Q4 2023, filed 13 Feb 2024.